ClinicalTrials.gg
RecruitingNCT07065591ADDEDUpdated Aug 18, 2026

Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight/Obesity

An Early Phase 1 interventional study of Metformin and Placebo in Osteoarthritis (OA) of the Knee, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Primary conditionOsteoarthritis, KneeRegistry: OsteoarthritisReclassifiedWhy we changed it
Registry
Osteoarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis, Knee
Why
  1. The study's title name Osteoarthritis, Knee, a narrower term within Osteoarthritis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The University of Hong Kong · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Osteoarthritis, Knee with a site in Hong Kong — 18 open to participants now, 20 under way, 1 of them phase 3. Osteoarthritis, Knee · Hong Kong.

Planned enrollment
15th of 42
100 · median 80
Started
2026
with 5 others
Phase 1
2 of 48
1 open now
Primary completion
2028-04
later than 16 of 19 live
Registered
42nd of 48
by date
Lead sponsor
7 of 48
The University of Hong Kong

Among the 48 studies in Osteoarthritis, Knee with a site in Hong Kong, this one is the 15th largest by planned enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 16 of the 19 other live ones, and was the 42nd registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

18 of the 48 studies in Osteoarthritis, Knee with a site in Hong Kong are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Osteoarthritis, Knee with a site in Hong Kong, or all of them as a file.
02

Study summary

Obesity is associated with increased pain with knee osteoarthritis and increase progression of knee osteoarthritis while weight loss intervention has been shown to reduce pain and requirement of total knee replacement. In this study, the investigators will assess using diet modification with exercise, and metformin, a common, safe, diabetes mellitus medication that has been in use for 70 years to achieve better weight control to reduce knee pain. This helps the investigators to understand whether the combined treatment can reduce joint pain, reduce body weight and improve symptoms and requirement of total knee replacement.

Read the detailed description

Unhealthy diet (high fat, sugar) and physical inactivity result in overweight/obesity, which is the major cause of knee osteoarthritis (KOA). KOA further leads to increased intake of comfort food (unhealthy diet) and reduced exercise due to knee pain, forming a vicious cycle. Overweight and obesity are the main risk factors for the major non-communicable diseases (NCDs) like diabetes, etc. which are additional exacerbating factors for KOA. Compared to other NCDs, KOA is more painful and disabling and therefore it commonly leads to early medical consultation for an obese individual. This provides a unique therapeutic opportunity to conduct weight control intervention and lifestyle modification when they are referred for management and waiting for total knee replacement (TKR). Achieving weight control can reduce their subsequent risk of development of other NCDs which lead to increased mortality, and potentially improve their osteoarthritic symptoms, and potentially avoid TKR.

Overweight and Obesity is defined as body mass index (BMI) exceeding 23 and 25 kg/m2 in Hong Kong respectively. Principal applicant (PA) reviewed the BMI of all KOA patients that subsequently had TKR in our hospitals and found the average BMI were 27.72 (2005-2009), 27.78 (2010-2015), and 28.07 (2016-2021) with the number of obese patients increased more than 6 times in 2016-2021 compared to 2005-2009. 73.74% of them were in obese class I and II in 2016- 2021, compared to just 33% of the whole Hong Kong population (same age group) were in these two classes (Based on Department of Health Population Health Survey). Obesity is disproportionally prevalent among KOA patients in Hong Kong with a worsening trend.

Studies and our pilot have found obese KOA patients have more medical comorbidities, with higher prevalence of metabolic syndrome, with more hypertension, dyslipidemia and impaired fasting glucose/diabetes. They are also associated with higher risks of cardiovascular disease, myocardial infarction, and stroke. Obesity is associated with greater pain while waiting for surgery but also with higher chances of developing various perioperative problems, such as surgical site infections, acute kidney injury, increased narcotics consumption, etc. compared to non-obese patients. Therefore, weight loss interventions for KOA are being explored recently to reduce the requirement of TKR, improve the health of KOA subjects, and improve the outcome if TKRs are eventually performed.

Diet modification to achieve weight loss with exercise therapy have been reported reducing KOA pain and improving physical function like walking distance and stair-climb time, compared to control in RCT (ADAPT trial). And it has been showed combining dietary weight loss and exercise can achieve better pain relief and joint loading than either dietary weight loss or exercise alone (Intensive Diet and Exercise for Arthritis (IDEA) trial). Despite these encouraging results, follow-up study at 3.5 years after initial intervention found participants experienced weight regain and reduced pain relief, suggesting difficulty in maintaining long-term weight loss. This matched our published Mendelian Randomization Study which found high BMI contributes to KOA more than effect of dietary intake.

Metformin, an oral anti-diabetic medication, is considered safe, affordable, and well-tolerated. It has been shown to promote weight loss and is a cost-effective option for long-term use on a large scale. Combining metformin with exercise and a balanced diet has been found to be more effective than using metformin alone. Metformin acts on pathways that are also involved in exercise, helping to reduce feelings of hunger and combat obesity. Additionally, metformin has anti-inflammatory and pain-relieving effects that can benefit individuals with osteoarthritis. Moreover, metformin has been shown to enhance muscle quality and reduce the process of muscle aging.

However, current trials using metformin on KOA did not (1) conduct with diet modification nor exercise therapy, (2) assess muscle improvement, (3) assess reduce in TKR, (4) effects of stopping metformin after changes are achieved.

Overall, metformin may accentuate effect of diet modification and exercise as they may be less reliant on comfort food and could perform exercise better (less hunger/pain/body weight and better muscle). This potentially break the vicious cycle of unhealthy diet/physical inactivity- obesity-osteoarthritis.

Trial objectives and Purpose The aim of the study is to determine metformin on top of exercise therapy and diet modification on reducing knee pain (VAS) over 6 months and increasing opt-out preference of joint replacement waiting list.

Hypothesis It is hypothesized that comparing with placebo, metformin will (1) reduce knee pain (primary outcome), (2) reduce body weight and (3) reduce the need of joint replacement.

Study design This is a randomized, double-blinded, placebo-controlled trial in patient with symptomatic knee OA and overweight or obesity, to determine metformin on top of exercise therapy and diet modification on reducing knee pain (VAS) over 6 months and increasing opt-out preference of joint replacement waiting list. Participants will undergo screening and follow-up at an Orthopaedic clinic, receive diet counseling and a structured exercise program, and then be randomly assigned to either metformin or a placebo for 6 months. Subsequently, there will be a 6-month period without medication, during which outcomes will be measured.

Study procedures:

Patients will be screened and followed up in Orthopaedic clinic, completing questionnaires, X-ray, blood glucose level test and blood tests, with blinded research assistants (RA) performing all measurements. Intervention will be started after initial screening confirming eligibility and consent signed.

Intervention:

All participants will undergo a modified Structured Nonsurgical Treatment Programme (SNTP) of Hospital Authority (HA) that references the IDEA trial. In this modified programme, both intervention and control group will receive diet counselling from dietitians with goal of achieving weight loss of 10% baseline body weight and initial diet plan of energy- intake deficit of 800-1000 kcals/day with minimal 1100 kcal for women and 1200 kcal for men and the calorie distribution goal following the Dietary Reference Intakes for Energy and Macronutrients and previous weight loss trials. Their body weight will be monitored during their scheduled nutrition counselling sessions with dietitians. They will also have exercise program with physiotherapists that are facility-based followed by home-based, and the standardized program consisting of an aerobic session (e.g. 15 min aerobic walking), a strength training session (20 min), a second aerobic session (15 min), and a cool-down session (10 min). The strength-training phase is designed to avoid any possible loss of muscle and bone mass resulting from dietary weight loss.

All patient will be prescribed with a standard dose of regular paracetamol and low dose non- steroid anti-inflammatory drugs instructed to be taken on as needed basis as painkillers, same as current normal practice for these patients.

While on diet modification and exercise therapy, patients will be randomly allocated to receive metformin (max: 500mgx4=2000mg daily)(intervention group) or placebos daily (control group). The placebos will be manufactured with Good Manufacturing Practice (GMP) standard such that each placebo pill will look like metformin pill (500mg). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only. The 6month medication period is based on several factors: Previous trials showing significant weight loss could be achieved by metformin with this timing and further extending the period may not produce much more weight reduction; 3-6months of metformin were showed to reduce arthritis pain; 4months of metformin improved handgrip strength, gait speed, and SPPB (muscle function/sarcopenia parameters); Importantly, a further 6 month period without medication will tell if continuing metformin is needed to maintain its benefit in weight reduction and pain relief. Therefore, this trial the investigators plan for 6months with medication followed by 6months without medication with outcome measurement.

Randomization and blinding:

Patients will be randomized in a 1:1 ratio to either group by computer generated sequence with block randomization. Allocation concealment and double blinding will be performed by: (1) medications being dispensed by centralized pharmacy only; (2) use of an identical placebo tablet, with scheduled gradual titration; (3) both groups will receive diet modification and exercise therapy such that patients, dietitians and physiotherapists will be blinded to group allocation; and (4) measurement by RA blinded to group allocation. Patients and assessors will be blinded to group allocation.

Safety:

Metformin has a well-known good drug safety profile as registered with the Drug Office, Department of Health. The investigators shall outline all potential adverse reactions in informed consent from common ones like nausea, abdominal pain, etc. to rare like lactic acidosis, etc. and these shall be regularly monitored and any of these will be reported to the ethic committee and funding body. They are closely monitored as they will be seen weekly during the 6-week drug titration, monthly clinic/phone follow-up, and assessment at 0, 3, 6, 12 months, as well as regular encounter with physiotherapists and dietitians.

03

Conditions studied

  • Osteoarthritis (OA) of the Knee

Browse trials for

Keywords

  • knee osteoarthritis
  • diet modification
  • exercise therapy
04

In context

Osteoarthritis, Knee Reclassified

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 100 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women age between 40 and 80 years old, with overweight or obesity ( ≥23 kg/m2) according to Hong Kong Centre for Health Protection definition of overweight and obesity.
  • Knee pain for 6+ months with Visual Analogue Scale (VAS) > 40mm/100mm and
  • Meet the American College of Rheumatology criteria for knee OA
  • OA referred for consideration for joint replacement

Exclusion criteria

Exclusion Criteria:

  • Severe radiographic knee OA (Kellgren-Lawrence grade 4) or severe knee pain (VAS>80mm/100 mm) that could not tolerate further conservative management;
  • inflammatory arthritis like rheumatoid arthritis, crystal arthritis, etc.
  • Preexisting diabetes on antidiabetic drug or drug allergy to metformin.
  • Recent knee surgery of the same knee
  • Significant bone loss.
  • Concomitant neuromuscular diseases affecting lower limb function.
  • renal or liver impairment precluding use of metformin.
  • VitaminB12 deficiency
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention group

    This group of patients will receive metformin (max: 500mgx4=2000mg daily). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.

    Drug: Metformin

  • Placebo comparator
    Placebo

    This group of patients will receive placebo. The placebos will be manufactured with Good Manufacturing Practice (GMP) standard such that each placebo pill will look like metformin pill (500mg). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.

    Other: Placebo

Interventions

  • The intervention group will receive metformin (max: 500mgx4=2000mg daily). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.

    Also known as: Metfomin

  • OtherPlacebo

    The placebo group will receive placebo. The placebos will be manufactured with Good Manufacturing Practice (GMP) standard such that each placebo pill will look like metformin pill (500mg). Both groups will start with an initial dose of 500mg daily and the dose will be gradually titrated to 2000mg daily in 6 weeks to allow patients adopting to the gastrointestinal symptoms. Both groups shall be put on metformin or placebo for 6months and then both groups will stop their respective medications and continue on diet modification and exercise therapy only.

07

What researchers measure

Primary outcomes

  1. Pain by visual analogue scale

    Measure the change in pain level through visual analogue scale (VAS) (0-100mm)

    Time frame: At 0,1.5, 3, 6 and 12 months

Secondary outcomes

  1. Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    Western Ontario and McMaster Universities Arthritis Index (WOMAC) consists of 24 items divided into 3 subscales Pain (5 items), Stiffness (2 items)Physical Function (17 items). The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. A sum of the scores for all three subscales gives a total WOMAC score.

    Time frame: At 0,1.5, 3, 6 and 12 months

  2. Body weight

    Body weight (kg - kilogram) will be measured at each visit.

    Time frame: At 0,1.5, 3, 6 and 12 months

  3. Knee stiffness

    It is measured by knee range measurement

    Time frame: At 0,1.5, 3, 6 and 12 months

  4. Physical Activity through questionnaire

    It is measured by the International Physical Activity Questionnaire short version. Results can be reported in categories (low activity levels, moderate activity levels or high activity levels) or as a continuous variable (MET minutes a week).

    Time frame: At 0,1.5, 3, 6 and 12 months

  5. Willingness to proceed TKR immediately

    It is measured as proxy of need of TKR.

    Time frame: At 0,1.5, 3, 6 and 12 months

  6. Physical performance of the muscle - walk

    It is measured by 6-metre walk: time to walk 6 metres without deceleration is taken (average of 2 trials is taken, cut-off \<1.0m/s).

    Time frame: At 0,1.5, 3, 6 and 12 months

  7. Physical performance of the muscle - chair stand

    It is measured by 5-time chair stand test: time to rise from chair 5 times is recorded (cut-off≥12 seconds).

    Time frame: At 0,1.5, 3, 6 and 12 months

  8. Physical performance of the muscle - balance

    It is measured by Short Physical Performance Battery (SPPB, cut-off\<=9). Patients will perform the balance test first, followed by the gait speed test, and finally the chair stand test. Each test will be scored individually, and the total score will be calculated by summing the scores of all three tests. The overall score ranges from 0 to 12, with 12 indicating the best performance.

    Time frame: At 0,1.5, 3, 6 and 12 months

  9. Muscle strength - Handgrip strength

    It is measured by spring-type handgrip dynamometer (JAMAR Hand Dynamometer) with dominant hand in a maximum-effort isometric contraction (cut-off=M: \<28 kg, F: \<18 kg)

    Time frame: At 0,1.5, 3, 6 and 12 months

  10. Appendicular skeletal muscle mass (ASM)

    It is measured by Bioelectrical impedance analysis (TANITA DC430MA (Tokyo, Japan) with a precision of 0.05 kg. with cut-off=M: \<7.0 kg/m2, F: \<5.7 kg/m2)

    Time frame: At 0,1.5, 3, 6 and 12 months

  11. Patient-reported outcome measure questionnaire

    It is measured by Sarcopenia and Quality of Life (SarQoL). The final version of the SarQoL® is composed of 55 items translated into 22 questions rated on a 4-point Likert scale. The questionnaire is scored on 100 points. Higher score reflects a higher quality of life.

    Time frame: At 0,1.5, 3, 6 and 12 months

  12. Kellgren-Lawrence grade

    It is measured at the X-ray, with grade 1, 2, 3 and 4.

    Time frame: At 0, 6, 12 months

  13. Compliance to the study

    It is a monthly phone/clinic follow-up to assess pill count for adherence

    Time frame: At every month, up to 1 year

  14. Blood glucose test.

    All patients will be received blood glucose test at baseline for fitness, 6months and 12 months, measured in mmol/L.

    Time frame: At baseline, 6 and 12 months

  15. Blood test - Complete blood count

    Complete blood count in thousand cells per microliter (K/μL).

    Time frame: At baseline, 6 and 12 months

  16. Blood test - Liver function test

    Liver/renal function test, level of alanine transaminase (ALT) and aspartate transaminase (AST).

    Time frame: At baseline, 6 and 12 months

  17. Blood test - renal function test

    Renal function test in Estimated Glomerular Filtration Rate (eGFR).

    Time frame: At baseline, 6 and 12 months

  18. Blood test - Vitamin B12

    Vitamin B12 in Picograms per milliliter (pg/mL).

    Time frame: At baseline, 6 and 12 months

  19. Blood test - Calcium phosphate

    Calcium phosphate in millimoles per liter (mmol/L).

    Time frame: At baseline, 6 and 12 months

  20. Blood test - Vitamin D

    Vitamin D in nanomoles per liter (nmol/L).

    Time frame: At baseline, 6 and 12 months

  21. Blood test - Bone profile

    Bone profile in millimoles per liter (mmol/L).

    Time frame: At baseline, 6 and 12 months

  22. Blood test - HbA1c

    HbA1c measures the average blood glucose levels over the past 2 to 3 months, expressed in percentage (%). Normal range below 6.4% in Hong Kong.

    Time frame: At baseline, 6 and 12 months

  23. Blood test - fasting glucose

    A fasting blood glucose test measures the blood sugar level after an overnight fast (usually 8-12 hours). Normal is \< 6.0mmol/L in Hong Kong.

    Time frame: At baseline, 6 and 12 months

  24. Blood test - lipids

    Cholesterol level in millimoles per litre (mmol/L).

    Time frame: At baseline, 6 and 12 months

08

Study locations

1 of 1 sites recruiting
  • Maclehose Medical Rehabilitation
    Hong Kong, Sandy Bay 999077, Hong Kong
    Recruiting
09

References and documents

Individual participant data

Plan to share: No — for further patient privacy protection

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Apr 2028, 19 months later.

Of 61 phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2025
First posted
Jul 15, 2025
StartEst.
Aug 30, 2026
Primary completionEst.
Apr 17, 2028
CompletionEst.
Jul 17, 2028
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07065591
Responsible party
Prof Lawrence Lau (Clinical Assistant Professor, The University of Hong Kong) — Principal investigator
First posted
Jul 15, 2025
Start date
Aug 30, 2026 (estimated)
Primary completion
Apr 17, 2028 (estimated)
Completion
Jul 17, 2028 (estimated)
Last update
Aug 18, 2026

Study contacts

Lawrence Lau, FRCS, PhD
Contact
laucml@hku.hk
+852 92646862

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion